dc.contributor.author |
Ugarte Gil, Cesar Augusto |
|
dc.contributor.author |
Elkington, Paul |
|
dc.contributor.author |
Gilman, Robert Hugh |
|
dc.contributor.author |
Coronel, Jorge |
|
dc.contributor.author |
Tezera, Liku B. |
|
dc.contributor.author |
Bernabé Ortiz, Antonio |
|
dc.contributor.author |
Gotuzzo Herencia, José Eduardo |
|
dc.contributor.author |
Friedland, Jon S. |
|
dc.contributor.author |
Moore, David Alexander James |
|
dc.date.accessioned |
2022-01-04T20:31:49Z |
|
dc.date.available |
2022-01-04T20:31:49Z |
|
dc.date.issued |
2013 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/10689 |
|
dc.description.abstract |
Introduction: Tuberculosis (TB) destroys lung tissues and this immunopathology is mediated in part by Matrix Metalloproteinases (MMPs). There are no data on the relationship between local tissue MMPs concentrations, anti-tuberculosis therapy and sputum conversion. Materials and Methods: Induced sputum was collected from 68 TB patients and 69 controls in a cross-sectional study. MMPs concentrations were measured by Luminex array, TIMP concentrations by ELISA and were correlated with a disease severity score (TBscore). 46 TB patients were then studied longitudinally at the 2nd, 8th week and end of treatment. Results: Sputum MMP-1,-2,-3,-8,-9 and TIMP-1 and -2 concentrations are increased in TB. Elevated MMP-1 and -3 concentrations are independently associated with higher TB severity scores (p<0.05). MMP-1, -3 and -8 concentrations decreased rapidly during treatment (p<0.05) whilst there was a transient increase in TIMP-1/2 concentrations at week 2. MMP-2, -8 and -9 and TIMP-2 concentrations were higher at TB diagnosis in patients who remain sputum culture positive at 2 weeks and MMP-3, -8 and TIMP-1 concentrations were higher in these patients at 2nd week of TB treatment. Conclusions: MMPs are elevated in TB patients and associate with disease severity. This matrix-degrading phenotype resolves rapidly with treatment. The MMP profile at presentation correlates with a delayed treatment response. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Public Library of Science |
|
dc.relation.ispartofseries |
PLoS ONE |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Cross-Sectional Studies |
en_US |
dc.subject |
Humans |
en_US |
dc.subject |
Case-Control Studies |
en_US |
dc.subject |
Longitudinal Studies |
en_US |
dc.subject |
Culture Techniques |
en_US |
dc.subject |
Antitubercular Agents |
en_US |
dc.subject |
Matrix Metalloproteinase 1 |
en_US |
dc.subject |
Matrix Metalloproteinase 3 |
en_US |
dc.subject |
Matrix Metalloproteinase 8 |
en_US |
dc.subject |
Matrix Metalloproteinases, Secreted |
en_US |
dc.subject |
Sputum |
en_US |
dc.subject |
Tissue Inhibitor of Metalloproteinases |
en_US |
dc.subject |
Tuberculosis |
en_US |
dc.title |
Induced Sputum MMP-1, -3 & -8 Concentrations during Treatment of Tuberculosis |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1371/journal.pone.0061333 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.03.08 |
|
dc.relation.issn |
1932-6203 |
|